Cello Therapeutics
San Diego, US · Founded 2016 · Delaware corporation
Biotech
Founders & leadership
LX
Lili XieNamed on SEC filing
HZ
Huiqing ZhuNamed on SEC filing
JZ
Jie ZhangNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$8.7M disclosed across 2 rounds · 2017–2022
▶$7.1MraisedAug 2022 · 3 investors · OtherRule 506(b)
▶$7.1MraisedAug 2022 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Jie ZhangExecutive Officer, Director
- Liangfang ZhangDirector
- Huiqing ZhuDirector
- Wei ShenDirector
- Offering amount
- $20.1M
- Amount sold
- $7.1M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJun 2017 · 5 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJun 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lili XieDirector
- Huiqing ZhuDirector
- Jie ZhangExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $1.6M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Cello Therapeutics raised?
- Cello Therapeutics has disclosed $8.7M raised across 2 rounds.
- Where is Cello Therapeutics headquartered?
- Cello Therapeutics is headquartered in San Diego, US.